Abstract Number: 2707 • 2018 ACR/ARHP Annual Meeting
Scleroderma Renal Crisis: The Association of High-Dose Steroids and Poor Outcome
Background/Purpose: Scleroderma renal crisis (SRC) is the most acute and life-threatening complication of scleroderma characterized by sudden increase in blood pressure and worsening kidney function.…Abstract Number: 1747 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcomes of Patients with Nonsevere Eosinophilic Granulomatosis with Polyangiitis Given Azathioprine and Glucocorticoids for Remission Induction
Background/Purpose: At month 24 (M24), CHUSPAN2-trial patients with nonsevere eosinophilic granulomatosis with polyangiitis (EGPA), who received 1 yr of azathioprine (AZA) and glucocorticoids (GC) as…Abstract Number: 2721 • 2018 ACR/ARHP Annual Meeting
Venous Thromboembolism in ANCA Associated Vasculitis. a Population-Based Cohort Study from Southern Sweden
Background/Purpose: To estimate the rate and predictors of venous thromboembolic events (VTEs) in a population-based cohort of patients with ANCA- associated vasculitis (AAV). Methods: 322…Abstract Number: 1846 • 2018 ACR/ARHP Annual Meeting
Menarchal Status at Diagnosis and Final Height in Females with Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: The diagnosis of systemic lupus erythematosus (SLE) in childhood affects growth due to disease and therapy. To date, there are few studies of final…Abstract Number: 2779 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome and Prognostic Factors after Aortic Valve Surgery Due to Aortic Valve Regurgitation in Patients with Takayasu Arteritis
Background/Purpose: Aortic valve (AV) surgery is often performed for aortic regurgitation (AR) in patients with Takayasu arteritis (TA). However, data on the long-term outcomes, including…Abstract Number: 296 • 2018 ACR/ARHP Annual Meeting
Does Care By a Multidisciplinary Team Improve Outcomes in Rheumatoid Arthritis? a Randomized Controlled Study
Background/Purpose: Quality standards recommend an annual review by a multidisciplinary team (MDT) for all patients with rheumatoid arthritis (RA); however, this is based on expert…Abstract Number: 1850 • 2018 ACR/ARHP Annual Meeting
A Population Based Study of High School Academic Outcomes in Individuals with Childhood-Onset Chronic Rheumatic Diseases in Manitoba, Canada
Background/Purpose: Childhood-onset chronic rheumatic diseases (ChildCRD) are rheumatic diseases with onset <18 years old, including juvenile arthritis (JA) and systemic autoimmune rheumatic diseases (SARD). ChildCRD…Abstract Number: 2876 • 2018 ACR/ARHP Annual Meeting
Torque Teno Virus Quantification for Functional Monitoring of Immunomodulation with Biological Compounds in the Treatment of Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) patients who fail to respond to methotrexate (MTX) can be subjected to an addition of biologic disease-modifying antirheumatic drug (bDMARD). Currently…Abstract Number: 459 • 2018 ACR/ARHP Annual Meeting
Readmission Rate within 30 Days of Hospitalization Due to New Onset Lupus Nephritis and Associated Risk Factors: The Importance of Intravenous Pulse Methylprednisolone Therapy
Background/Purpose: There is a paucity of data regarding the early hospital readmission rates in newly diagnosed childhood lupus nephritis (cLN). We conducted a retrospective study…Abstract Number: 1882 • 2018 ACR/ARHP Annual Meeting
Characteristics and Treatment Outcomes of Takayasu Arteritis in a Nationwide, Retrospective Cohort Study in Japan
Background/Purpose: Takayasu arteritis (TAK) typically affects young women under 40 years old, whereas patients with onset age over 40 years are occasionally observed. It still…Abstract Number: 477 • 2018 ACR/ARHP Annual Meeting
Early Treatment with Intravenous Pulse Methylprednisolone or Methotrexate Is Associated with Decreased Medication Requirements at 12 and 24 Months in Patients with Juvenile Dermatomyositis: A Propensity Score Analysis
Background/Purpose: Daily oral prednisone has been the main therapy in juvenile dermatomyositis (JDM), and combination therapy with methotrexate (MTX) introduced soon after diagnosis has been…Abstract Number: 2359 • 2018 ACR/ARHP Annual Meeting
Systemic Lupus Erythematous Outcome Concerns: Identifying Pain As the Major Discrepancy between Rheumatologists and Patients
Background/Purpose: Now-a-days there is a growing trend of switching to a more patient-centered healthcare system, with a widespread use of patient-reported outcomes (PROs). However, most…Abstract Number: 604 • 2018 ACR/ARHP Annual Meeting
Combining Observational and Randomized Controlled Trial Data Evidence to Jointly Estimate Remission and Response for Biologic and Non-Biologic Therapies in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis
Background/Purpose: Remission is the goal of rheumatoid arthritis (RA) treatment, but ACR responses are more commonly measured in clinical trials. As such, data on remission…Abstract Number: 2406 • 2018 ACR/ARHP Annual Meeting
Clinical Presentation, Management and Long Term Outcome of Pars Planitis (PP), Panuveitis (PU) and Vogt–Koyanagi–Harada Disease (VKH) in Children and Adolescents
Background/Purpose: Chronic uveitis is a common manifestation of pediatric rheumatologic conditions and may result in irreversible blindness and long term disability. While chronic anterior uveitis…Abstract Number: 717 • 2018 ACR/ARHP Annual Meeting
The Burden of Chronic Kidney Disease in Systemic Lupus Erythematosus (SLE): A Nationwide Epidemiologic Study
Background/Purpose: Lupus nephritis occurs in about 50% of SLE patients. We aimed to analyze the impact of chronic kidney disease (CKD) on major clinical outcomes…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 10
- Next Page »